Two Japanese drugmakers eye U.S. market

Japan's Toyama City-based Nichi-Iko Pharmaceutical and Osaka-based Sawai Pharmaceutical plan to expand their products to the U.S. market. Nichi-Iko is looking to sell new drugs there and not the generics it has relied on, while Sawai will release generics in the American market. Nichi-Iko, Japan's largest generics maker, said it plans to apply to the U.S. Food and Drug Administration next year for approval to manufacture one new drug. It anticipates approval being given in 2018 and generating sales of ¥3 billion ($25.2 million). The company did not disclose what type of drug it hoped to have approved in the U.S. but is said to be preparing U.S. sales of biosimilars. Sawai, the second-largest generics maker in Japan, has already applied for approval for its generic version of lipid-lowering Livalo and expects to start sales in March 2018, according to a report by Nikkei news. Report

Suggested Articles

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.